# Biomed Valley Discoveries

Source: https://onco.cc/companies/biomed-valley-discoveries/  
OnCo record `biomed-valley-discoveries` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biomed Valley Discoveries is a Kansas City company owned through the Stowers Institute for Medical Research. Its main medicine, ulixertinib, blocks ERK, the last step of a growth signalling chain that is switched on in many cancers and in histiocytosis.

## Summary

Biomed Valley Discoveries, Inc. (BVD) describes itself as a clinical-stage biotechnology company based in Kansas City, Missouri, wholly owned by a supporting organisation of the non-profit Stowers Institute for Medical Research and funded through American Century Investments. Its lead programme is ulixertinib (BVD-523), which the company calls a highly selective ERK1/2 inhibitor, in phase 2 development; its website lists histiocytosis (NCT06411821), adult and paediatric low- and high-grade glioma (NCT05804227) and myelofibrosis with ruxolitinib (NCT06773195) as its priorities, and says a paediatric low-grade glioma trial is planned for 2026. It also lists TEM8/ANTXR1 antibodies for antibody-drug conjugates (preclinical) and a Clostridium novyi-NT bacterial programme whose phase 1 is complete. The FDA designated ulixertinib an orphan drug for BRAF-mutant melanoma in 2013, and on 27 August 2026 granted the company a designation for malignant glioma for a product it describes as a reversible ATP-competitive ERK1/2 inhibitor.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: BioMed Valley Discoveries, Inc.; Biomed Valley Discoveries Inc.; BVD
- HQ: Kansas City, MO
- Type: biotech
- Website: https://biomed-valley.com/

## Notes

- The 2026 FDA record does not name the product; ulixertinib is the only ERK1/2 inhibitor on the company's pipeline. The window-of-opportunity glioma trial NCT05804227 is sponsored by MD Anderson Cancer Center and the histiocytosis trial NCT06411821 by Memorial Sloan Kettering. Read on 4 November 2026.

## Sources

- Official website: https://biomed-valley.com/
- Ulixertinib programme page: https://biomed-valley.com/ulixertinib/
- FDA orphan designation, malignant glioma, 27 August 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1173826
- FDA orphan designation of ulixertinib, melanoma, 2013: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=398213

## Connected records

- cancers: [Erdheim-Chester disease](https://onco.cc/cancers/erdheim-chester-disease/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MAPK1](https://onco.cc/targets/mapk1/), [MAPK3](https://onco.cc/targets/mapk3/)
- drugs: [Ulixertinib](https://onco.cc/drugs/ulixertinib/)

---
JSON: https://onco.cc/api/v1/entities/biomed-valley-discoveries.json